Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease　― Recent Insights Focusing on Angiogenesis and Neovascularization ―

DOI Web Site Web Site PubMed 10 Citations 60 References Open Access
  • Lei Yanna
    Department of ICU, Yanbian University Hospital
  • Hu Lina
    Department of Public Health, Guilin Medical College
  • Yang Guang
    Department of Cardiology, Yanbian University Hospital
  • Piao Limei
    Department of Cardiology, Yanbian University Hospital
  • Jin Minggen
    Department of ICU, Yanbian University Hospital
  • Cheng Xianwu
    Department of Cardiology, Yanbian University Hospital Institute of Innovation for Future Society, Nagoya University Department of Cardiovascular Internal Medicine, Kyung Hee University Hospital, Kyung Hee University

Bibliographic Information

Other Title
  • Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease — recent insights focusing on angiogenesis and neovascularization

Search this article

Description

<p>Dipeptidyl peptidase IV (DPP-IV) is a complex enzyme that acts as a membrane-anchored cell surface exopeptidase and transmits intracellular signals through a small intracellular tail. DPP-IV exists in human blood in a soluble form, and truncates a large number of peptide hormones, chemokines, cytokines, and growth factors in vitro and in vivo. DPP-IV has gained considerable interest as a therapeutic target, and a variety of DPP-IV inhibitors that prolong the insulinotropic effects of glucagon-like peptide-1 (GLP-1) are widely used in clinical settings as antidiabetic drugs. Indeed, DPP-IV is upregulated in proinflammatory states, including obesity and cardiovascular disease with and without diabetes mellitus. Consistent with this maladaptive role, DPP-IV inhibitors seem to exert a protective role in cardiovascular disease. In addition to their GLP-1-dependent vascular protective actions, DPP-IV inhibitors exhibit GLP-1-independent beneficial effects on angiogenesis/neovascularization via several signaling pathways (e.g., stromal cell-derived factor-1α/C-X-C chemokine receptor type-4, vascular endothelial growth factor-A/endothelial nitric oxide synthase, etc.). This review focuses on recent findings in this field, highlighting the role of DPP-IV in therapeutic angiogenesis/neovascularization in ischemic heart disease and peripheral artery disease.</p>

Journal

  • Circulation Journal

    Circulation Journal 81 (6), 770-776, 2017

    The Japanese Circulation Society

Citations (10)*help

See more

References(60)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top